Respiratory Syncytial Virus (RSV) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500

Respiratory syncytial virus (RSV) infection infects the lungs and breathing passages. RSV commonly causes bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children less than one year of age.

The Respiratory Syncytial Virus pipeline market research report provides comprehensive information on the therapeutics under development for Respiratory Syncytial Virus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Respiratory Syncytial Virus and features dormant and discontinued projects.

Respiratory Syncytial Virus Pipeline Products Market Segmentation by Targets

The key targets in the Respiratory Syncytial Virus pipeline products market are Respiratory Syncytial Virus Fusion Protein, Respiratory Syncytial Virus Attachment Glycoprotein, Respiratory Syncytial Virus RNA Directed RNA Polymerase L, Nucleocapsid Protein, Pulmonary Surfactant Associated Protein D, Respiratory Syncytial Virus Nucleoprotein, Toll Like Receptor 4, ATP Dependent RNA Helicase DDX3X, Complement C1q Subcomponent, Envelope Protein M, and others.

Respiratory Syncytial Virus Pipeline Products Market Analysis by Targets

Respiratory Syncytial Virus Pipeline Products Market Analysis by Targets

For more target insights into the Respiratory Syncytial Virus pipeline products market, download a free report sample

Respiratory Syncytial Virus Pipeline Products Market Segmentation by Mechanisms of Action

The key mechanisms of action in the Respiratory Syncytial Virus pipeline products market are Respiratory Syncytial Virus Fusion Protein Inhibitor, Respiratory Syncytial Virus Attachment Glycoprotein Inhibitor, Respiratory Syncytial Virus RNA Directed RNA Polymerase L Inhibitor, Pulmonary Surfactant Associated Protein D Replacement, ATP Dependent RNA Helicase DDX3X Inhibitor, Complement C1q Subcomponent Inhibitor, Envelope Protein M Inhibitor, Exportin 1 Inhibitor, Fatty Acid Synthase Inhibitor, Glucocorticoid Receptor Agonist, and others.

Respiratory Syncytial Virus Pipeline Products Market Analysis by Mechanisms of Action

Respiratory Syncytial Virus Pipeline Products Market Analysis by Mechanisms of Action

For more mechanisms of action insights into the Respiratory Syncytial Virus pipeline products market, download a free report sample

Respiratory Syncytial Virus Pipeline Products Market Segmentation by Routes of Administration

The key routes of administration in the RSV pipeline products market are intramuscular, nasal, oral, intravenous, inhalational, parenteral, intradermal, and intrapulmonary.

Respiratory Syncytial Virus Pipeline Products Market Analysis by Routes of Administration

Respiratory Syncytial Virus Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights into the Respiratory Syncytial Virus pipeline products market, download a free report sample

Respiratory Syncytial Virus Pipeline Products Market Segmentation by Molecule Types

The key molecule types in the Respiratory Syncytial Virus pipeline products market are small molecule, subunit vaccine, monoclonal antibody, live attenuated vaccine, recombinant vector vaccine, mRNA vaccine, vaccine, recombinant protein, peptide, antisense RNAi oligonucleotide, and others.

Respiratory Syncytial Virus Pipeline Products Market Analysis by Molecule Types

Respiratory Syncytial Virus Pipeline Products Market Analysis by Molecule Types

For more molecule type insights into the Respiratory Syncytial Virus pipeline products market, download a free report sample

RSV Pipeline Products Market - Competitive Landscape

Some of the leading companies in the RSV pipeline products market are Johnson & Johnson, Merck & Co Inc, Shanghai Ark Biopharmaceutical Co Ltd, AstraZeneca Plc, Moderna Inc, Pfizer Inc, Sanofi, Enanta Pharmaceuticals Inc, GSK plc, and TechnoVax Inc.

Respiratory Syncytial Virus Pipeline Products Market Analysis by Companies

Respiratory Syncytial Virus Pipeline Products Market Analysis by Companies

To know more about the leading players in the Respiratory Syncytial Virus pipeline products market, download a free report sample

Respiratory Syncytial Virus Pipeline Products Market Report Overview

Key Targets Respiratory Syncytial Virus Fusion Protein, Respiratory Syncytial Virus Attachment Glycoprotein, Respiratory Syncytial Virus RNA Directed RNA Polymerase L, Nucleocapsid Protein, Pulmonary Surfactant Associated Protein D, Respiratory Syncytial Virus Nucleoprotein, Toll Like Receptor 4, ATP Dependent RNA Helicase DDX3X, Complement C1q Subcomponent, Envelope Protein M, and Others
Key Mechanisms of Action Respiratory Syncytial Virus Fusion Protein Inhibitor, Respiratory Syncytial Virus Attachment Glycoprotein Inhibitor, Respiratory Syncytial Virus RNA Directed RNA Polymerase L Inhibitor, Pulmonary Surfactant Associated Protein D Replacement, ATP Dependent RNA Helicase DDX3X Inhibitor, Complement C1q Subcomponent Inhibitor, Envelope Protein M Inhibitor, Exportin 1 Inhibitor, Fatty Acid Synthase Inhibitor, Glucocorticoid Receptor Agonist, and Others
Key Routes of Administration Intramuscular, Nasal, Oral, Intravenous, Inhalational, Parenteral, Intradermal, and Intrapulmonary
Key Molecule Type Small Molecule, Subunit Vaccine, Monoclonal Antibody, Live Attenuated Vaccine, Recombinant Vector Vaccine, mRNA Vaccine, Vaccine, Recombinant Protein, Peptide, Antisense RNAi Oligonucleotide, and Others
Leading Companies Johnson & Johnson, Merck & Co Inc, Shanghai Ark Biopharmaceutical Co Ltd, AstraZeneca Plc, Moderna Inc, Pfizer Inc, Sanofi, Enanta Pharmaceuticals Inc, GSK plc, and TechnoVax Inc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Respiratory Syncytial Virus (RSV) Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Abhelix LLC
Abivax SA
ADMA Biologics Inc
Advac LLC
Advagene Biopharma Co Ltd
AIM Vaccine Co Ltd
Airway Therapeutics Inc
AlloVir Inc
Anima Biotech Inc
Aposense Ltd
Aridis Pharmaceuticals Inc
Artificial Cell Technologies Inc
AstraZeneca Plc
Atea Pharmaceuticals Inc
Atriva Therapeutics GmbH
Auro Vaccines LLC
AVM Biotechnology LLC
Bavarian Nordic AS
Beijing Advaccine Biotechnology Company Ltd
BioComo Inc
Biological E Ltd
Blue Lake Biotechnology Inc
BlueWillow Biologics Inc
BravoVax Co Ltd
Calder Biosciences Inc
Celestial Therapeutics Inc
Changchun Bcht Biotechnology Co Ltd
Chengdu Aoda Biotechnology Co Ltd
Chongqing Zhifei Biological Products Co Ltd
Cidara Therapeutics Inc
Clover Biopharmaceuticals Ltd
Codagenix Inc
ConserV Bioscience Ltd
Curevac NV
CyanVac LLC
Daiichi Sankyo Co Ltd
Enanta Pharmaceuticals Inc
Enyo Pharma SA
Esperovax Inc
Eucure (Beijing) Biopharma Co Ltd
Exopharm Ltd
F. Hoffmann-La Roche Ltd
Gilead Sciences Inc
GSK plc
HanaVax Inc
Heartland Vaccines LLC
iBio Inc
Icosavax Inc
IDBiologics Inc
ILiAD Biotechnologies LLC
Immunwork Inc
Imophoron Ltd
IMV Inc
Inhalon Biopharma Inc
Inovio Pharmaceuticals Inc
Intravacc BV
Johnson & Johnson
KARE Biosciences Inc
Karyopharm Therapeutics Inc
Kidswell Bio Corp
Mapp Biopharmaceutical Inc
Meissa Vaccines Inc
Merck & Co Inc
MicroQuin Ltd
Moderna Inc
Navigen Inc
NeuClone Pty Ltd
Neuracle Science Co Ltd
Novavax Inc
Oita University Institute of Advanced Medicine Inc
Pfizer Inc
Pinetree Therapeutics Inc
Pneumagen Ltd
Poolbeg Pharma Plc
Prime Vector Technologies GmbH
Primmune Therapeutics Inc
Prosit Sole Biotechnology (Beijing) Co Ltd
ReAlta Life Sciences Inc
Revelation Biosciences Inc
Riboscience LLC
Romark Laboratories LC
Ruiyang (Suzhou) Biotechnology Co Ltd
Sagimet Biosciences Inc
Sanofi.
Sciwind Biosciences Co Ltd
Shandong Danhong Pharmaceutical Co Ltd
Shanghai Ark Biopharmaceutical Co Ltd
Shionogi & Co Ltd
Sigmovir Biosystems Inc
Signia Therapeutics
SK Bioscience Ltd
Taisho Pharmaceutical Holdings Co Ltd
TechnoVax Inc
Trimunocor Ltd
TrippBio Inc
Uvax Bio LLC
Vault Pharma Inc
Vaxart Inc
Vaxxel SAS
Vicebio Ltd
Vir Biotechnology Inc
Viramatix Sdn Bhd
Viravaxx AG
Virometix AG
Visterra Inc
VLP Biotech Inc
X4 Pharmaceuticals Inc
XBiotech Inc
Zhuhai Trinomab Biotechnology Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Respiratory Syncytial Virus (RSV) Infections – Overview

Respiratory Syncytial Virus (RSV) Infections – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Respiratory Syncytial Virus (RSV) Infections – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Respiratory Syncytial Virus (RSV) Infections – Companies Involved in Therapeutics Development

Respiratory Syncytial Virus (RSV) Infections – Drug Profiles

(human metapneumovirus + human respiratory syncytial virus) (bivalent) vaccine – Drug Profile

Product Description

Mechanism Of Action

(human parainfluenza virus [serotype 1] + respiratory syncytial virus) vaccine – Drug Profile

Product Description

Mechanism Of Action

(influenza (virus like particle) + respiratory syncytial virus) vaccine – Drug Profile

Product Description

Mechanism Of Action

(influenza + Coronavirus Disease 2019 (COVID-19) + respiratory syncytial virus) vaccine – Drug Profile

Product Description

Mechanism Of Action

(pertussis + respiratory syncytial virus) vaccine – Drug Profile

Product Description

Mechanism Of Action

ABX-196 – Drug Profile

Product Description

Mechanism Of Action

ADV-110 – Drug Profile

Product Description

Mechanism Of Action

AK-0529 – Drug Profile

Product Description

Mechanism Of Action

AK-0610 – Drug Profile

Product Description

Mechanism Of Action

AK-0611 – Drug Profile

Product Description

Mechanism Of Action

AK-0702 – Drug Profile

Product Description

Mechanism Of Action

ALVR-106 – Drug Profile

Product Description

Mechanism Of Action

Antisense RNAi Oligonucleotide for Respiratory Syncytial Virus (RSV) Infections – Drug Profile

Product Description

Mechanism Of Action

AR-201 – Drug Profile

Product Description

Mechanism Of Action

ASN-500 – Drug Profile

Product Description

Mechanism Of Action

AVG-388 – Drug Profile

Product Description

Mechanism Of Action

AZ-27 – Drug Profile

Product Description

Mechanism Of Action

B-1402 – Drug Profile

Product Description

Mechanism Of Action

BC-0005 – Drug Profile

Product Description

Mechanism Of Action

BC-0335 – Drug Profile

Product Description

Mechanism Of Action

BL-200 – Drug Profile

Product Description

Mechanism Of Action

BLB-201 – Drug Profile

Product Description

Mechanism Of Action

CAL-100 – Drug Profile

Product Description

Mechanism Of Action

CDX-RSV – Drug Profile

Product Description

Mechanism Of Action

clesrovimab – Drug Profile

Product Description

Mechanism Of Action

CR-32T – Drug Profile

Product Description

Mechanism Of Action

CT-02 – Drug Profile

Product Description

Mechanism Of Action

dexamethasone sodium phosphate – Drug Profile

Product Description

Mechanism Of Action

DPX-RSV – Drug Profile

Product Description

Mechanism Of Action

Drugs for Respiratory Syncytial Virus – Drug Profile

Product Description

Mechanism Of Action

Drugs for Viral Infections – Drug Profile

Product Description

Mechanism Of Action

DSCav-1 – Drug Profile

Product Description

Mechanism Of Action

EDP-323 – Drug Profile

Product Description

Mechanism Of Action

EDP-938 – Drug Profile

Product Description

Mechanism Of Action

Fusion Proteins for Coronavirus Disease 2019 (COVID-19) and Respiratory Syncytial Virus (RSV) Infections – Drug Profile

Product Description

Mechanism Of Action

GSK-3844766A – Drug Profile

Product Description

Mechanism Of Action

GSK-3888550A – Drug Profile

Product Description

Mechanism Of Action

HEVS-124 – Drug Profile

Product Description

Mechanism Of Action

IB-004R – Drug Profile

Product Description

Mechanism Of Action

immune globulin (human) – Drug Profile

Product Description

Mechanism Of Action

infectious disease vaccine – Drug Profile

Product Description

Mechanism Of Action

IVX-121 – Drug Profile

Product Description

Mechanism Of Action

IVXA-12 – Drug Profile

Product Description

Mechanism Of Action

JNJ-64213175 – Drug Profile

Product Description

Mechanism Of Action

JNJ-64400141 – Drug Profile

Product Description

Mechanism Of Action

JNJ-7184 – Drug Profile

Product Description

Mechanism Of Action

JNJ-78991172 – Drug Profile

Product Description

Mechanism Of Action

JNJ-86051823 – Drug Profile

Product Description

Mechanism Of Action

MM-002 – Drug Profile

Product Description

Mechanism Of Action

MM-004 – Drug Profile

Product Description

Mechanism Of Action

molnupiravir – Drug Profile

Product Description

Mechanism Of Action

Monoclonal Antibodies for Respiratory Syncytial Virus (RSV) Infections – Drug Profile

Product Description

Mechanism Of Action

Monoclonal Antibody for Respiratory Syncytial Virus – Drug Profile

Product Description

Mechanism Of Action

Monoclonal Antibody for Respiratory Syncytial Virus Infections – Drug Profile

Product Description

Mechanism Of Action

Monoclonal Antibody to Inhibit RSV F Protein for Respiratory Syncytial Virus Infections – Drug Profile

Product Description

Mechanism Of Action

MPE-8 – Drug Profile

Product Description

Mechanism Of Action

MPE-8 – Drug Profile

Product Description

Mechanism Of Action

MRIRSM-01 – Drug Profile

Product Description

Mechanism Of Action

MRKV-171 – Drug Profile

Product Description

Mechanism Of Action

mRNA-1230 – Drug Profile

Product Description

Mechanism Of Action

mRNA-1345 – Drug Profile

Product Description

Mechanism Of Action

mRNA-1365 – Drug Profile

Product Description

Mechanism Of Action

MV-012968 – Drug Profile

Product Description

Mechanism Of Action

MVA-BN RSV – Drug Profile

Product Description

Mechanism Of Action

Neumifil – Drug Profile

Product Description

Mechanism Of Action

nirsevimab – Drug Profile

Product Description

Mechanism Of Action

nitazoxanide CR – Drug Profile

Product Description

Mechanism Of Action

P-220241 – Drug Profile

Product Description

Mechanism Of Action

palivizumab biobetter – Drug Profile

Product Description

Mechanism Of Action

palivizumab biosimilar – Drug Profile

Product Description

Mechanism Of Action

palivizumab biosimilar – Drug Profile

Product Description

Mechanism Of Action

palivizumab biosimilar – Drug Profile

Product Description

Mechanism Of Action

pertussis [strain BPZE1] vaccine – Drug Profile

Product Description

Mechanism Of Action

PF-06928316 – Drug Profile

Product Description

Mechanism Of Action

PF-07923567 – Drug Profile

Product Description

Mechanism Of Action

POLB-002 – Drug Profile

Product Description

Mechanism Of Action

Polysaccharides for Viral Infections – Drug Profile

Product Description

Mechanism Of Action

Product Candidates – Drug Profile

Product Description

Mechanism Of Action

Protein for Respiratory Syncytial Virus Infection – Drug Profile

Product Description

Mechanism Of Action

PRTX-007 – Drug Profile

Product Description

Mechanism Of Action

PSP-008 – Drug Profile

Product Description

Mechanism Of Action

ramatroban – Drug Profile

Product Description

Mechanism Of Action

RB-0026 – Drug Profile

Product Description

Mechanism Of Action

RBS-3149 – Drug Profile

Product Description

Mechanism Of Action

Recombinant Protein for Infectious Disease and Oncology – Drug Profile

Product Description

Mechanism Of Action

Recombinant Protein for RSV Infections – Drug Profile

Product Description

Mechanism Of Action

Recombinant Surfactant Associated Protein D Replacement for SARS and RSV Infections – Drug Profile

Product Description

Mechanism Of Action

respiratory syncytial virus (virus like particle) vaccine – Drug Profile

Product Description

Mechanism Of Action

respiratory syncytial virus (virus like particle) vaccine – Drug Profile

Product Description

Mechanism Of Action

respiratory syncytial virus (virus like particle) vaccine – Drug Profile

Product Description

Mechanism Of Action

respiratory syncytial virus (virus like particle) vaccine – Drug Profile

Product Description

Mechanism Of Action

respiratory syncytial virus (virus like particle) vaccine – Drug Profile

Product Description

Mechanism Of Action

respiratory syncytial virus (virus like particle) vaccines – Drug Profile

Product Description

Mechanism Of Action

respiratory syncytial virus (virus like particles) vaccine – Drug Profile

Product Description

Mechanism Of Action

respiratory syncytial virus [strain 98-25147-X] vaccine – Drug Profile

Product Description

Mechanism Of Action

respiratory syncytial virus [strain A/Maryland/001/11] vaccine – Drug Profile

Product Description

Mechanism Of Action

respiratory syncytial virus vaccine – Drug Profile

Product Description

Mechanism Of Action

respiratory syncytial virus vaccine – Drug Profile

Product Description

Mechanism Of Action

respiratory syncytial virus vaccine – Drug Profile

Product Description

Mechanism Of Action

respiratory syncytial virus vaccine – Drug Profile

Product Description

Mechanism Of Action

respiratory syncytial virus vaccine – Drug Profile

Product Description

Mechanism Of Action

respiratory syncytial virus vaccine – Drug Profile

Product Description

Mechanism Of Action

respiratory syncytial virus vaccine – Drug Profile

Product Description

Mechanism Of Action

respiratory syncytial virus vaccine – Drug Profile

Product Description

Mechanism Of Action

respiratory syncytial virus vaccine – Drug Profile

Product Description

Mechanism Of Action

respiratory syncytial virus vaccine – Drug Profile

Product Description

Mechanism Of Action

respiratory syncytial virus vaccine – Drug Profile

Product Description

Mechanism Of Action

respiratory syncytial virus vaccine – Drug Profile

Product Description

Mechanism Of Action

respiratory syncytial virus vaccine – Drug Profile

Product Description

Mechanism Of Action

respiratory syncytial virus vaccine – Drug Profile

Product Description

Mechanism Of Action

respiratory syncytial virus vaccine – Drug Profile

Product Description

Mechanism Of Action

respiratory syncytial virus vaccine – Drug Profile

Product Description

Mechanism Of Action

respiratory syncytial virus vaccine – Drug Profile

Product Description

Mechanism Of Action

respiratory syncytial virus vaccine – Drug Profile

Product Description

Mechanism Of Action

respiratory syncytial virus vaccine – Drug Profile

Product Description

Mechanism Of Action

respiratory syncytial virus vaccine – Drug Profile

Product Description

Mechanism Of Action

respiratory syncytial virus vaccine – Drug Profile

Product Description

Mechanism Of Action

respiratory syncytial virus vaccine – Drug Profile

Product Description

Mechanism Of Action

respiratory syncytial virus vaccine – Drug Profile

Product Description

Mechanism Of Action

respiratory syncytial virus vaccine – Drug Profile

Product Description

Mechanism Of Action

respiratory syncytial virus vaccine – Drug Profile

Product Description

Mechanism Of Action

respiratory syncytial virus vaccine – Drug Profile

Product Description

Mechanism Of Action

respiratory syncytial virus vaccine 1 – Drug Profile

Product Description

Mechanism Of Action

respiratory syncytial virus vaccine 1 – Drug Profile

Product Description

Mechanism Of Action

respiratory syncytial virus vaccine 1 – Drug Profile

Product Description

Mechanism Of Action

respiratory syncytial virus vaccine 1 – Drug Profile

Product Description

Mechanism Of Action

respiratory syncytial virus vaccine 2 – Drug Profile

Product Description

Mechanism Of Action

respiratory syncytial virus vaccine 3 – Drug Profile

Product Description

Mechanism Of Action

respiratory syncytial virus vaccine 3 – Drug Profile

Product Description

Mechanism Of Action

respiratory syncytial virus vaccine 4 – Drug Profile

Product Description

Mechanism Of Action

respiratory syncytial virus vaccine 5 – Drug Profile

Product Description

Mechanism Of Action

respiratory syncytial virus vaccine 6 – Drug Profile

Product Description

Mechanism Of Action

respiratory syncytial virus vaccine 7 – Drug Profile

Product Description

Mechanism Of Action

respiratory syncytial virus vaccines – Drug Profile

Product Description

Mechanism Of Action

REVTx-99 – Drug Profile

Product Description

Mechanism Of Action

rilematovir – Drug Profile

Product Description

Mechanism Of Action

RLS-0071 – Drug Profile

Product Description

Mechanism Of Action

RSV – Drug Profile

Product Description

Mechanism Of Action

RSV – Drug Profile

Product Description

Mechanism Of Action

RSV – Drug Profile

Product Description

Mechanism Of Action

RSV – Drug Profile

Product Description

Mechanism Of Action

RSV Antivirals – Drug Profile

Product Description

Mechanism Of Action

RSV Artificial Intelligence Drug Discovery Program – Drug Profile

Product Description

Mechanism Of Action

RSV DFC – Drug Profile

Product Description

Mechanism Of Action

RSV Program – Drug Profile

Product Description

Mechanism Of Action

RSV Vaccine – Drug Profile

Product Description

Mechanism Of Action

RSV-276 – Drug Profile

Product Description

Mechanism Of Action

RSV-F005 – Drug Profile

Product Description

Mechanism Of Action

S-337395 – Drug Profile

Product Description

Mechanism Of Action

sisunatovir hydrochloride – Drug Profile

Product Description

Mechanism Of Action

Small Molecule 1 for Respiratory Syncytial Virus Infections – Drug Profile

Product Description

Mechanism Of Action

Small Molecule for Respiratory Syncytial Virus (RSV) Infections – Drug Profile

Product Description

Mechanism Of Action

Small Molecule for Respiratory Syncytial Virus Infections – Drug Profile

Product Description

Mechanism Of Action

Small Molecule to Inhibit RSV F Protein for Respiratory Syncytial Virus Infection – Drug Profile

Product Description

Mechanism Of Action

Small Molecules 2 for Respiratory Syncytial Virus Infections – Drug Profile

Product Description

Mechanism Of Action

Small Molecules for Respiratory Syncytial Virus (RSV) Infections – Drug Profile

Product Description

Mechanism Of Action

Small Molecules for Respiratory Syncytial Virus Infections – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit RSV F Protein for Respiratory Syncytial Virus Infection – Drug Profile

Product Description

Mechanism Of Action

SP-0125 – Drug Profile

Product Description

Mechanism Of Action

Syncytial Virus Fusion Inhibitor – Drug Profile

Product Description

Mechanism Of Action

TCB-029 – Drug Profile

Product Description

Mechanism Of Action

TD-214 – Drug Profile

Product Description

Mechanism Of Action

TE-4308 – Drug Profile

Product Description

Mechanism Of Action

TNM-001 – Drug Profile

Product Description

Mechanism Of Action

TP-0591816 – Drug Profile

Product Description

Mechanism Of Action

TRL-3D3 – Drug Profile

Product Description

Mechanism Of Action

TVB-3567 – Drug Profile

Product Description

Mechanism Of Action

TVX-004IP – Drug Profile

Product Description

Mechanism Of Action

verdinexor – Drug Profile

Product Description

Mechanism Of Action

VIS-RSV – Drug Profile

Product Description

Mechanism Of Action

VMT-3 – Drug Profile

Product Description

Mechanism Of Action

VMTX-002 – Drug Profile

Product Description

Mechanism Of Action

VN-0200 – Drug Profile

Product Description

Mechanism Of Action

VPI-251 – Drug Profile

Product Description

Mechanism Of Action

VXB-211 – Drug Profile

Product Description

Mechanism Of Action

VXX-005 – Drug Profile

Product Description

Mechanism Of Action

WLBU-2 – Drug Profile

Product Description

Mechanism Of Action

XW-001 – Drug Profile

Product Description

Mechanism Of Action

YH-009 – Drug Profile

Product Description

Mechanism Of Action

zapnometinib – Drug Profile

Product Description

Mechanism Of Action

zelpultide alfa – Drug Profile

Product Description

Mechanism Of Action

Respiratory Syncytial Virus (RSV) Infections – Dormant Projects

Respiratory Syncytial Virus (RSV) Infections – Discontinued Products

Respiratory Syncytial Virus (RSV) Infections – Product Development Milestones

Featured News & Press Releases

Oct 23, 2022: GSK’s older adult respiratory syncytial virus (RSV) vaccine candidate shows

94.1% reduction in severe RSV disease and overall vaccine efficacy of

82.6% in pivotal trial

Oct 18, 2022: Enanta doses first participant in Phase I RSV treatment trial

Oct 07, 2022: Ark Biopharmaceutical presents positive results in phase 3 AIRFLO study of ziresovir in RSV-infected hospitalized infants at 12th International RSV Symposium

Oct 04, 2022: Enanta commences Phase IIb trial of RSV treatment

Oct 04, 2022: Icosavax initiates phase 1 trial of IVX-A12 against RSV and hMPV in older adults

Oct 02, 2022: Enanta Pharmaceuticals announces new preclinical data for its respiratory virology programs to be presented at the 12th International RSV Symposium

Sep 29, 2022: Enanta Pharmaceuticals presents preclinical data for its respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) programs at the 12th International RSV Symposium

Sep 16, 2022: Beyfortus (nirsevimab) recommended for approval in the EU by CHMP for the prevention of RSV lower respiratory tract disease in infants

Aug 26, 2022: Pfizer reports positive Phase III data for bivalent RSV vaccine in adults

Aug 12, 2022: NIHR and Sanofi announce first patient enrolled in large European clinical study to investigate protection against RSV, the leading cause of infant hospitalisation worldwide

Jul 22, 2022: Blue Lake enrols first subject in Phase I RSV vaccine trial

Jun 28, 2022: Icosavax announces positive topline interim phase 1/1b results for VLP vaccine candidate IVX-121 against RSV

Jun 28, 2022: Bavarian Nordic announces grant of PRIME eligibility from the European Medicines Agency for its RSV vaccine candidate for the prevention of respiratory syncytial virus in older adults

Jun 24, 2022: Oral antiviral drug effective against respiratory syncytial virus (RSV) identified by biomedical sciences researchers

Jun 13, 2022: GSK reports positive Phase III data for RSV vaccine in elderly

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Respiratory Syncytial Virus (RSV) Infections – Dormant Projects, 2022

Respiratory Syncytial Virus (RSV) Infections – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Respiratory Syncytial Virus (RSV) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,500

Can be used by individual purchaser only

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Respiratory Syncytial Virus (RSV) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Respiratory Syncytial Virus (RSV) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.